Abstract Library

#2136 Combination of Capecitabine and Temozolomide for Advanced Thymic Neuroendocrine Tumors

Introduction: In vitro data indicate that the combination of capecitabine(CAP) and temozolomide(TEM) is synergistic for induction of apoptosis in neuroendocrine tumor cell lines. It has been proven that the CAPTEM regimen is associated with an exceptionally high and durable response rate in patients with metastatic pancreatic neuroendocrine tumors. However, there is less evidence to illustrate if the CAPTEM regimen is effective for thymic neuroendorine tumors(TNET).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Tan H

Authors: Wang X, Li Y, Shi Y, Chen Y, Qiu X,

Keywords: thymic neuroendocrine tumors, capecitabine, temozolomide, progress-free survival, adverse effect,

#1856 Relationship Between Symptoms and HRQoL Benefits in Patients (pts) with Carcinoid Syndrome (CS): A Post-Hoc Analysis of Telotristat Ethyl (TE) TELESTAR Trial

Introduction: TELESTAR previously demonstrated the efficacy and safety of TE in pts with CS experiencing >4 Bowel Movements (BM) per day despite stable-dose somatostatin analog therapy. Significantly higher rates of Durable Response (DR, predefined as Bowel Movement (BM) frequency reduction ≥30% from baseline for ≥50% of the 12 week double blind period) were observed with TE (TE 250mg: 44%, TE 500mg: 42%) vs placebo (20%).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Cella D

Authors: Cella D, Beaumont J, Hudgens S, Marteau F, Feuilly M,

Keywords: telotristat ethyl, HRQoL, carcinoid syndrome,

#1354 Patient Interviews in TELESTAR, a Phase 3 Study of Telotristat Etiprate, Report Meaningful Improvement in Carcinoid Syndrome

Introduction: Telotristat etiprate (TE) reduces serotonin production. In TELESTAR, a phase 3 study in patients (pts) with carcinoid syndrome (CS) on somatostatin analogues with ≥4 bowel movements (BM) per day, TE significantly reduced BM frequency (freq). Overall (n=135), durable response (DR, ≥30% reduction in BMs/day for ≥50% of the study period) was observed in 44% (250 mg tid) and 42% (500 mg tid), vs 20% on placebo (PBO); p≤0.02 for each TE vs. PBO. A subset with similar demographics to the overall trial was interviewed.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Pavel M, Hörsch D, Anthony L, Ervin C, Kulke M,

Keywords: serotonin, bowel movement, durable response, treatment satisfaction,

#1008 STZ-Based Chemotherapy is Associated with Durable Response Rate in Pancreatic NET as 1st or 2nd Line Treatment

Introduction: The role of chemotherapy for pancreatic neuroendocrine tumors (pNETs) is controversially discussed. Objective response rates (RR) with streptozocin (STZ)-based chemotherapy are variable. Novel targeted drugs have recently been approved.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Dilz L

Authors: Dilz L, Denecke T, Arsenic R, Steffen I, Pape U,

Keywords: pancreatic NET, Ki-67, chemotherapy, streptozotocin,

#709 Temozolomide and Capecitabine: An Effective Combination in Metastasic G2 NETs

Introduction: Treatment of neuroendocrine tumors (NETs) with chemotherapy has been validated in different studies. Recently a retrospective trial demonstrated high and durable response rate with Temozolomide and Capecitabine in 30 pancreatic NETs (pNETs).

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Barrio M, García R, Garcia E, Medina K, Arbeloa B,

Keywords: neuroendocrine, temozolomide, capecitabine,